Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Press Micronesia.
Press releases published on June 20, 2025
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
GlobeNewswire
·
June 20, 2025
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late- …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 20, 2025
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
GlobeNewswire
·
June 20, 2025
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase …
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
GlobeNewswire
·
June 20, 2025
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc …
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
GlobeNewswire
·
June 20, 2025
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced …
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire
·
June 20, 2025
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a …
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
GlobeNewswire
·
June 20, 2025
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with …
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
GlobeNewswire
·
June 20, 2025
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
SlimJaro Advanced Weight Loss Supplement in 2025: Can Targeting Inflammation Extra Body Fat, Read Slim Jaro Benefits & Side Effects
GlobeNewswire
·
June 20, 2025
New York City, NY, June 20, 2025 (GLOBE NEWSWIRE) -- In 2025, weight loss has become more complicated than simply cutting calories or hitting the gym. Many people around the world are following standard health advice yet still struggle with slow or …
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and …
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché NANTES, France, 20 juin 2025, 19 heures 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; …
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
GlobeNewswire
·
June 20, 2025
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel …
Rakovina Therapeutics Announces Share Consolidation Effective Date
GlobeNewswire
·
June 20, 2025
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “ …
Dr. Myung Ju Lee Shared Enhanced Deep-Plane Facelift Technique at ISAPS Olympiad World Congress
GlobeNewswire
·
June 20, 2025
JEJU, South Korea, June 20, 2025 (GLOBE NEWSWIRE) -- Dr. Myung Ju Lee, MD, PhD, Chief Surgeon at VIP Plastic Surgery Clinic in Jeju, South Korea, a leading Korean plastic surgery clinic, presented groundbreaking research on facelift innovation at the …
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
GlobeNewswire
·
June 20, 2025
Four-year data show preservation of cardiac function, including LVEF Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) Deramiocel’s long-term safety profile remains favorable Results presented at PPMD’s 2025 Annual …
Moleculin Announces $5.9 Million Public Offering
GlobeNewswire
·
June 20, 2025
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the …
INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time
GlobeNewswire
·
June 20, 2025
SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility focused company, reminds shareholders to vote their shares online ahead of the upcoming annual meeting of …
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
GlobeNewswire
·
June 20, 2025
CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult- …
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
GlobeNewswire
·
June 20, 2025
SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and …
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
GlobeNewswire
·
June 20, 2025
– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology …